DE3777709D1 - Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis. - Google Patents

Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.

Info

Publication number
DE3777709D1
DE3777709D1 DE8787305410T DE3777709T DE3777709D1 DE 3777709 D1 DE3777709 D1 DE 3777709D1 DE 8787305410 T DE8787305410 T DE 8787305410T DE 3777709 T DE3777709 T DE 3777709T DE 3777709 D1 DE3777709 D1 DE 3777709D1
Authority
DE
Germany
Prior art keywords
gardiasis
deoxythymidin
azido
treating
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787305410T
Other languages
English (en)
Inventor
Richard Lee Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE3777709D1 publication Critical patent/DE3777709D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE8787305410T 1986-06-19 1987-06-18 Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis. Expired - Fee Related DE3777709D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87623486A 1986-06-19 1986-06-19

Publications (1)

Publication Number Publication Date
DE3777709D1 true DE3777709D1 (de) 1992-04-30

Family

ID=25367239

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787305410T Expired - Fee Related DE3777709D1 (de) 1986-06-19 1987-06-18 Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.

Country Status (3)

Country Link
EP (1) EP0253517B1 (de)
JP (1) JPH07103035B2 (de)
DE (1) DE3777709D1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051361A (en) * 1988-10-19 1991-09-24 Sigma Chemical Company AZT immunoassays, derivatives, conjugates and antibodies
US5288489A (en) * 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
US5378232A (en) * 1991-08-28 1995-01-03 Orion Therapeutic Systems, Inc. Injection/activation apparatus

Also Published As

Publication number Publication date
JPH07103035B2 (ja) 1995-11-08
JPS6310729A (ja) 1988-01-18
EP0253517A3 (en) 1989-09-06
EP0253517B1 (de) 1992-03-25
EP0253517A2 (de) 1988-01-20

Similar Documents

Publication Publication Date Title
DE3585607D1 (de) Verwendung von paroxetine zur herstellung eines arzneimittel zur behandlung von obesitaet.
DE3887625D1 (de) Verfahren zur Herstellung von 1,1,1-Trifluorodichlorethan und von 1,1,1,2-Tetrafluorchlorethan.
DE68928956T2 (de) Verfahren zur Herstellung von optisch aktivem 1,3-Butanediol
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
DE68927703D1 (de) Verfahren zur Herstellung von 2,3-Dimethylbutenen
DE3785740D1 (de) Verwendung von carboxamid-verbindungen zur herstellung eines arzneimittels zur behandlung der hyperlipaemie.
DE68927949D1 (de) 3,9-Diphosphaspiroundecane und Verfahren zur Herstellung von 3,9-Diphosphaspiroundecanen
DE3583220D1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
ATA232687A (de) Zahnpflegemittel, sowie verfahren zur herstellung des zahnpflegemittels
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
DE3675115D1 (de) Verwendung von verbindungen zur herstellung eines medikaments fuer die behandlung von grauem star.
DE69019052T2 (de) Verfahren zur Herstellung von 2'Deoxy-5-trifluoromethyl-ss-uridin.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE3777709D1 (de) Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.
DE68915067T2 (de) Verfahren zur Herstellung von 2'-Deoxy-beta-adenosin.
DE68922507D1 (de) Verfahren zur Herstellung von beta-2',2'-Difluornukleosiden.
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
ATE11911T1 (de) N-(1-allyl-2-pyrrolidinyl-methyl)-2-methoxy-4amino-5-methylsulfamoyl-benzamide, verfahren zur herstellung und verwendung als heilmittel.
DE68906700T2 (de) Verwendung eines polypeptids zur herstellung einer zusammensetzung zur behandlung von pankreatitis.
ATE57912T1 (de) Verfahren zur herstellung von anilinofumarat und 2,3-chinolindicarbonsaeure.
DE3580665D1 (de) Verwendung von doxaminol zur herstellung eines arzneimittels zur behandlung der peripheren arteriellen verschlusskrankheit.
DE68906465T2 (de) Verfahren zur Herstellung von 2,3-Dimethoxy-5-Methylbenzochinon.
DE68920493D1 (de) Verfahren zur Herstellung von Derivaten von 2'-Deoxy-beta-cytidin und Salze davon.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee